All News

EULAR,Podcast,2021

EULAR 2021 - Day 2 Podcasts

Jack Cush, MD

Check out this compilation of our EULAR 2021 Day 2 broadcasts below.



You can also follow the EULAR 2021 RheumNow podcasts on iTunes and Soundcloud.com



Listen by Clicking below:

Read Article
RheumNow Podcast square

RheumNow Podcast - EULAR 2021 & EULAR-IQ (6.4.21)

Jack Cush, MD

Dr Jack Cush reviews highlight presentations from the first 3 days of EULAR 2021.


Read Article
computer.health.jpg (keep)

EULAR Best Abstracts - Day 2

Jack Cush, MD

The second day of EULAR 2021 took a big leap in online content.  #EULAR2021 generated 2500 tweets yesterday. Here is a compilation (with links) of presentations were the “Best” as seen by our RheumNow faculty. 

Read Article
Lupus.right_.jpg

Is Rituximab and Belimumab the Combination to Beat Lupus?

Eric Dein, MD

On day 2 of EULAR conference, Dr. Michael Ehrenstein presented OP0129, a presentation on the BEAT-LUPUS trial looking at belimumab therapy after rituximab. B cell depletion with rituximab is common treatment for refractory SLE, though real-world data for rituximab has been uncertain. It is known that B-cell activating factor (BAFF) levels can increase after rituximab, which can lead to disease flares. Using belimumab, a human monoclonal antibody inhibiting BAFF, could be a potential therapeutic option after rituximab infusions. 

Read Article
acr_session2.jpeg

EULAR 2021 – Day 2 Report

Jack Cush, MD

During Day 2 there were great sessions devoted to RA, spondylarthritis, fatigue and more.  Here are some of my highlights from Day 2.

Read Article
lung%2Cbright.jpg

New insights in RA-ILD therapeutics

Aurelie Najm, MD, PhD

RA associated ILD (RA-ILD) is the most common extra-articular manifestation in RA. Its prevalence varies considerably, ranging from 5% to 30%, and is often underestimated since patients only become symptomatic or display abnormalities on chest X-Ray at a late stage of disease, leading to subsequent delay in diagnosis. In this context, several groups advocate for an earlier and more precise detection, using high resolution chest computed tomography (HRCT), which is the most sensitive for pre-clinical RA-ILD diagnosis.
But why would we want to diagnose early a manifestation that we cannot treat?

Read Article
LNA043 - modified, recombinant human angiopoietin-like 3 (ANGPTL3) protein ⭐️proof of concept trial on patients with articular cartilage lesions ⭐️regeneration of damaged cartilage ⭐️treatment effect in cartilage volume ⭐️phase IIb pending Abs#POS0277 #EULAR2021 @RheumNow

Robert B Chao, MD doctorRBC ( View Tweet)

#EULAR2021 Pres6882 @Rheumnow. Excellent summary slide by Dr. Elena Nikiphorou with 10 great take-home messages to share with your patient on diet and rheumatic disease. https://t.co/N7mq73KzLF
Eric Dein ejdein1 ( View Tweet)
What's your ideal anti-rheumatic diet? #EULAR Pres6882 @Rheumnow @andreafava

Eric Dein ejdein1 ( View Tweet)

A single dose of LORECIVIVINT IA (Wnt pathway modulator) in Phase 3 study in knee OA: mild improvement of WOMAC pain -8.16[-15.60, -0.71] P=0.032 and function -9.47[-17.09, -1.84] P=0.015 at 6 and 12months with no particular safety signal. #POS0278 #EULAR2021 @RheumNow https://t.co/5qQE6MPjnU
Aurelie Najm AurelieRheumo ( View Tweet)
Poster #POS1031 pooled VOYAGE 1&2 and DISCOVER 1&2, GI-related SAE rates low. No uveitis, opportunistic infections, or new onset/exacerbation of IBD in GUS-treated pts. No new safety concerns were identified through 1-year follow up. #EULAR2021 @RheumNow https://t.co/7NxeOu6FLW

Links:

Dr. Rachel Tate uptoTate ( View Tweet)

How to Measure Success in Lupus? Dr. Kathryn Dao ( @KDAO2011 ) https://t.co/z8c8moIQCa #EULAR2021

Links:

Dr. John Cush RheumNow ( View Tweet)

We need to look after #mentalhealth (MH) of #SLE patients.Dr Petri studied large US database. MH prevalence = 36%(SLE) and 29%(Nephritis;LN).LN with MH stayed 7.2 days longer in-patient vs without MH. Health cost/year⬆️in SLE+MH ($49,553 vs $26,064) #EULAR2021 #POS0304 @RheumNow https://t.co/wa7XmJxx9O
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
#EULAR2021 and EULAR IQ Dr Jack Cush reviews highlight presentations from the first 3 days of EULAR 2021. https://t.co/BkHjhOUqNU https://t.co/4JS1yGiJHg

Links:

Dr. John Cush RheumNow ( View Tweet)
Sex Differences in Autoimmune Disease Susceptibility: Drs. Yusof and Robinson Dr. Yusof interviews Dr. Robinson about abstract OP0013 presented at the virtual #EULAR2021 meeting. https://t.co/IPe6lMM7NQ https://t.co/Dt36N3OhZg

Links:

Dr. John Cush RheumNow ( View Tweet)
What is the impact of RA on fertility in men: #OP0211 and #OP0212 @Rheumnow #EULAR2021

Aurelie Najm AurelieRheumo ( View Tweet)

HOT🔥: thermography of hands in IA remotely collected via smartphone correlates w/ US features 0.48, p<0.01 and SJC 0.48, p<0.01), DAS28 (0.73, p<0.01), CDAI (0.84, p<0.01) and SDAI (0.82, p<0.01). A future tool for patients remote follow-up? #OP0300 @Rheumnow #EULAR2021 https://t.co/MJLpz6eqIy
Aurelie Najm AurelieRheumo ( View Tweet)
#OP0228 Phase 3 RCT on Risankizumab - KEEPsAKE 2 -PsA with 49% prior bDMARD 95% prior csDMARD: week 24 results PE: ACR20 51% active vs 26% on PLC PASI90: 55% active vs. 10% PLC #EULAR2021 @RheumNow https://t.co/UkZLcXTNnq
Paul Studenic Stiddyo ( View Tweet)
What's your EULAR IQ? Test your knowledge! #EULAR2021 https://t.co/psumBpzUc7 https://t.co/w5Vg68RVLs

Links:

Dr. John Cush RheumNow ( View Tweet)
IL-17i expressed in overuse tendinopathy. Secukinumab for tx of rotator cuff tendinopathy? ⭐️Phase II study - no difference in rotator cuff score (WORC) vs placebo ⭐️no difference in pain score Abs#POS0022 #EULAR2021 @RheumNow

Robert B Chao, MD doctorRBC ( View Tweet)

How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×